Galecto Inc. announced the issuance of a warrant to purchase up to 628,302 shares of its common stock to Paramora Holding LLC as part of an antibody discovery and option agreement with Paragon Therapeutics, Inc. and Paramora. The warrant has an exercise price of $23.01 per share, equal to the closing price on December 31, 2025, and will expire ten years from the issue date. The company relied on the exemption from registration requirements provided by Section 4(a)(2) under the Securities Act of 1933, as the transaction involved a single accredited investor and did not constitute a public offering.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Galecto Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-003490), on January 06, 2026, and is solely responsible for the information contained therein.